Nature

Adalimumab suppresses markers of structural damage in ankylosing spondylitis

Therapy with anti-tumor necrosis factor agents improves the symptoms of ankylosing spondylitis (AS); however, evaluation of these agents' disease-modifying capability in placebo-controlled trials is ...
Healio

Adalimumab, IBI303 biosimilar demonstrate comparable safety, efficacy in AS

Please provide your email address to receive an email when new articles are posted on . IBI303, a biosimilar to adalimumab developed by Chinese biopharmaceutical company Innovent Biologics, is ...
Nasdaq

Innovent Biologics Study Results of IBI303 in Patients with Ankylosing Spondylitis was Published in "The Lancet Rheumatology"

SUZHOU, China, Aug. 30, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today ...
Pharmabiz

AbbVie to present data from multiple studies of Rinvoq, Humira & Skyrizi at the 2019 ACR/ARP) meeting

AbbVie to present data from multiple studies of Rinvoq, Humira & Skyrizi at the 2019 ACR/ARP) meeting: North Chicago, Illionis Tuesday, November 5, 2019, 16:00 Hrs [IST] AbbVie, a ...
Healio

Median survival of first-line TNF inhibitor in ankylosing spondylitis nearly 11 years

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The median survival time of first-line anti-TNF therapy ...
National Institute for Health and Care Excellence

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people ...
Business Insider

Innovent Announces NMPA Granted New Indication Approval for SULINNO® (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis

SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
Monthly Prescribing Reference

Uveitis Risk Compared Among TNF Inhibitors in Ankylosing Spondylitis

Certain types of tumor necrosis factor (TNF) agents may affect the recurrence of uveitis in Behcet disease (BD) patients, while not affecting the occurrence of uveitis in patients with ankylosing ...
Business Insider

HADLIMA® (adalimumab injection) Now Available for the Treatment of Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing ...

HADLIMA ® is a biosimilar biologic drug (biosimilar) to the reference biologic drug HUMIRA ®. A biosimilar is authorized based on its similarity to a reference biologic drug that was already ...
Medscape

Some Biologics May Be Better Than Others for Averting Anterior Uveitis

Among patients with ankylosing spondylitis or undifferentiated spondyloarthritis, risk for anterior uveitis may hinge on the choice of biologic disease-modifying antirheumatic drug (bDMARD), a large ...
Medscape

FDA Approves Yuflyma as Ninth Adalimumab Biosimilar

The US Food and Drug Administration (FDA) has approved the biosimilar adalimumab-aaty (Yuflyma) in a citrate-free, high-concentration formulation, the manufacturer, Celltrion USA, announced today. It ...